Translating Effective Cessation to Underserved Populations: What Barriers? Matthew J. Carpenter, PhD, Marvella E. Ford, PhD, Kathleen Cartmell, MPH, Anthony.

Slides:



Advertisements
Similar presentations
What Smokers Want (focus on blue-collar workers) Elizabeth M. Barbeau, ScD, MPH Dana-Farber Cancer Institute Harvard School of Public Health.
Advertisements

Le-Edged Sword Risks, Rewards and the Double-Edged Sword: Views of Pharmacogenetic Testing and Research in the Alaska Native/American Indian Community.
STAGES OF CHANGE Precontemplation Contemplation Action Maintenance Relapse Not yet considering quitting Thinking about quitting Making a quit attempt Remaining.
Smoking and mental health Mark Allen Specialist Health Improvement Practitioner.
Quit Information Seminar. Aims of session To: help you to understand why people smoke provide information about quitting methods and products discuss.
Tobacco.
Presinted by :Shahd Amer.  Tobacco ads may make you feel like everyone is doing it but they are not.  Only about 28% of high school students smoke.
All About Smoking Cessation Going for the 3 Increases: Increase in Health, Increase in Happiness & Increase in Energy Strategies for Success in Health.
Prevention strategies
Smoking Cessation. Opportunity for Physicians 70 percent of smokers want to quit. Without assistance only 5 percent are able to quit. Most try to quit.
HIV Clinical Trials Janice Price, M.Ed, RN HIV Clinical Research Program Coordinator Swedish Medical Center Seattle, WA USA.
Telehealthcare: Integrating service development and evaluation Tracy Finch, Carl May, Frances Mair, Maggie Mort, Linda Gask Universities of Newcastle,
How You Can Be an Advocate for Clinical Trials in Your Community.
© Business & Legal Reports, Inc Alabama Retail is committed to partnering with our members to create and keep safe workplaces. Be sure to check out.
Focus Groups Preliminary Information Maureen Black BSC RRT COPD Coordinator, Health PEI Anja Salijevic BSC CHES, Health Promotion Assistant, Canadian Cancer.
Stop smoking or stop breathing By : Karen Bonilla 2nd period.
ENHANCED OUT-OF-SCHOOL TIME ACTIVITIES FOR MIDDLE SCHOOL STUDENTS IN PROVIDENCE, RHODE ISLAND Presented by Julie Pokela, Ph.D. Market Street Research,
Study Design Population Sampling Frame Interview Length
Social Problems in the United States
Evidence-based/Best Practices Tobacco Control Hadii Mamudu, PhD, MPA COPH-China Institute November 17, 2011.
Smoking Cessation in the Military: Challenges, Solutions, And Issues for Women Smokers Robert C. Klesges, Ph.D. Professor, Department of Preventive Medicine,
Department of Medicine Daily smoking has declined, but nondaily smoking is rising especially among young adults Nondaily smokers make up 22-36% of adult.
Choosing to Live Tobacco- Free Teens and Tobacco Benefits of living Tobacco-Free Quitting Tobacco Use.
Quit Information Seminar. Aims of session To: help you to understand why people smoke provide information about quitting methods and products discuss.
Quit For Life® Program Presented by Helen Farid 1.
Reasons Why People Smoking and Ways To Quit By: Abbie Reeves.
Clearing the Air: What You Need to Know and Do to Prepare to Quit Smoking Getting Ready to Quit Course May,2011 Sponsored by: Baltimore County Health Department.
Tobacco harm reduction: NICE guidance and recent developments Linda Bauld.
Tobacco Myths- Up in Smoke (American Cancer Society) HS 460.
Medication Adherence The following module is designed as a basic overview of medication adherence for providers of healthcare, particularly those in a.
Findings from Focus Groups of Geriatric Patients Regarding Medication Issues Kate Lynn Lapane, PhD Virginia Commonwealth University.
 2008 Johns Hopkins Bloomberg School of Public Health Evaluating Mass Media Anti-Smoking Campaigns Marc Boulay, PhD Center for Communication Programs.
Towards Educating and Engaging the American-Muslim Community in the National Dialogue on ELSI of Genomic Technologies Khaled Bouri, Ph.D.; MPH Food and.
Laws/Policies ABSTRACT Problem: A challenge for tobacco control practitioners is getting smokers to quit using cessation methods. To increase the proportion.
Increasing Access to Pharmacotherapy Jonathan P. Winickoff, MD, MPH Associate Professor in Pediatrics Harvard Medical School April 26, 2013.
Early Adolescent African American Girls’ Views about Sex and Pregnancy Gwendolyn D. Childs, PhD, RN Reashanda White Connie Hataway, RN, MSN.
Smoke Free Musical By Eugenie Shin and Saki Nagai.
Addressing Nicotine Dependence in Drug Treatment Kimber Paschall Richter, PhD, MPH Robert M. McCool, MS University of Kansas School of Medicine, Kansas.
Attempting to increase the use of smoking cessation medications Brendon Baker Ministry of Health.
LGBT Tobacco Prevention & Control National Association of Lesbian, Gay, Bisexual and Transgender Community Centers.
BDH Discovering Tomorrow’s Healthcare Solutions Today Clinical Research Services, Inc. Basil Halliday, M.Sc. President & CEO BDH Clinical Research Services.
Efficacy of Combination First Line Agents for Smoking Cessation Sneha Baxi, Pharm.D. Pharmacy Practice Resident University of Illinois at Chicago.
5/18/09 TMAAAPHP Tobacco Control Task ForceSlide 1 Tobacco Harm Reduction  Buyer/Hagan/Burr v. Kennedy/Waxman  A Public Health Perspective  Live Video.
-Tobacco is the leading preventable cause of disease, disability, and death in the United States (NIDA, 2012). -About 1 in every 5 deaths in the U.S. result.
1 Behaviour change in theory and in real life Robert West University College London Stockholm, April 2008.
By: Thien Bui and Reshma Neupane 1. Lung Cancer Lung Cancer is an uncontrolled growth of abnormal cells in one or more lungs 2 Common Types of Lung Cancer:
Addressing Tobacco Use in Mental Health Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester.
1 Advising smokers on optimum pharmacotherapy for smoking cessation University College London April 2014 Robert West.
Addressing Tobacco Use in Medical Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester School.
Tobacco treatment TrAining Network in Crete Tobacco treatment TrAining Network in Crete.
Internal Barriers to Seeking Smoking Cessation Treatment John Hughes, M.D.
Attitudes to smoking and drinking in pregnancy and their effect on the delivery of health interventions Faculty of Public Health Scotland Dr Debbie Wason.
Jump to first page 1 Models of Health Promotion n Stages of Change, Prochaska et al (1982) n Health Belief Model, Rosenstock (1974)
Tobacco CHAPTER – Facts About Tobacco Tobacco is a woody, shrub-like plant with large leaves. These leaves are harvested and prepared for smoking.
1 Tobacco smoking: where are we now and what can be done to reduce prevalence? Robert West University College London Cardiff, April 2008.
Why and How to Quit Smoking
Tobacco Cessation Guidelines for COPD
Drugs & Alcohol PC Jane Commins.
Smoking cessation Felix K. Karthik.
Mindfulness-based Smoking Cessation among
Freshstart Facilitator Training
To Vape, or Not to Vape, Facts FOR Students David SuDA, M.ED, LPC
Vaping Ask students if they have heard of vaping (or vapes, e-cigarettes). What have they heard?
Smoking Cessation Smoke Signals.
Lauren A. Cripps, MA, Melissa B. Gilkey, PHD,
Lauren A. Cripps, MA, Melissa B. Gilkey, PHD,
Tobacco Cessation for Primary Care Providers
Mobile Apps/Resources
Presentation transcript:

Translating Effective Cessation to Underserved Populations: What Barriers? Matthew J. Carpenter, PhD, Marvella E. Ford, PhD, Kathleen Cartmell, MPH, Anthony Alberg, PhD, MPH Hollings Cancer Center, Medical University of South Carolina, Charleston, SC Background: Disparities in quitting success among ever-smokers: Many smokers unaware of effective cessation tools Survey of 616 smokers in Ontario 1 : - 20% failed to recall any proven pharmacotherapy aid - 24% cited at least 1 unproven cessation strategy (e.g., hypnosis) - 78% stated that, if motivated to quit, they would be as successful on their own as with help Nicotine Replacement Therapy (NRT) well documented to improve quitting success Underuse of proven cessation strategies is a big problem, particularly among minority smokers NHIS data: 78% of smokers who tried to quit in past year did so unaided 2 Not just about cost: - In VA (equal access health system) – 34% of AA smokers, 26% of Hispanic smokers, and 50% of Caucasian smokers ever used NRT 3 Likely barriers: perceived efficacy, perceived safety While studies have examined barriers to NRT use, few have used a qualitative approach to capture detailed information about beliefs or examined beliefs across race/ethnic groups This study examines individual factors by race / ethnicity that may inhibit the use of NRT into widespread public health benefit Acknowledgments: Funding provided through the American Cancer Society (IRG ). The authors wish to thank Jason Roberson for assistance in conducting focus groups and Lindy McQuinn with assistance with data analysis. Correspondence: Matthew Carpenter: Specific Aims: To examine qualitative and detailed perspectives on NRT across and within groups of smokers using focus group methodology Predominant Themes Among African Americans Strong Suspicion of Pharmaceutical Industry / Government (FDA): “I’m thinking ‘are you sure that’s not a placebo you wear’ - they’re telling you that it’s used to cut back the nicotine craving. Is there actual medication in there or is it something like a test, where you have some of the people getting the active pills and there’s no medication in the others” “sometimes they slip somebody a little money under the table to put this stuff on the market and before you know it somebody done croaked and they either recall or get sued” “some of these research programs- people are going to cover up in order to get their products [out], but it’s the drug companies that are paying to get there products out there on the market” “with everything else they could just go around the authorities” “Are the cigarette companies selling those (NRT products)? When the price of cigarettes goes up, the price of NRT goes up too. The cigarette company is probably selling that product too” “It’s all part of the government. Everyone gets part of the reward from the sale of cigarette tobacco. If there’s something they could do to stop, they would stop, but they don’t want to do that because the change is going to affect a lot of people” Power of Doctor’s Advice: “the doctor is going to know what type of health condition you have, to determine whether you should be taking any one of those NRTs” “the doctor knows your health and whether you can handle the medication, or whether the other medication you’re taking (is going to react)” “If my doctor gave it to me, then I would use it. Because he knows my background” “I think I would want my doctor to take my body’s metabolism and my physical health and connect it to whatever one he feels is best for me. And to be straight up front as to what that the effects could be” “I think you should see your physician before you start anything. You know because some things just don’t combine. You know it may have chemical reactions” Supremacy of ‘Cold Turkey’: “Cause you don’t have to worry about being addicted to those stuff, that nasal spray out there, or using the gum all day” “[using NRT is] adding on the problem. If you take that, you’re just going to stop for a while, then you’re going right back at it” Conclusions: General lack of knowledge of NRT effects, efficacy; moderate knowledge on mechanism Universal concerns about NRT safety; EA smokers more likely to endorse addictive potential Among AA smokers  strong suspicion of pharmaceutical industry & government oversight Reliance on ineffective strategies: “at least with cold turkey its free & you’re not hurting yourself” More education needed with regard to NRT development, process of testing: safety / efficacy AA smokers could be educated through trusted physicians Methods: Six focus groups conducted homogeneous to race - 3 with European Americans (EA), 3 with African Americans (AA) - 7 to 12 members per group; total N=53 (27 AAs and 26 EAs) Groups heterogeneous with regard to prior NRT use Locations in public libraries Individuals recruited in person & through flyers at local community businesses Moderators race-matched & trained on focus group methodology Exclusive focus on NRT – rationale based on ubiquity of NRT (OTC status) Adjunctive survey on smoking history, attitudes about NRT $75 reimbursement (2-3 hour total) Data analyzed through Qualitative Data Analysis (NVivo): - transcripts coded and organized for thematic nodes Focus Group Topics: 1) consequences of continued smoking 2) what NRT is, its mechanism, and the rationale for using it 3) perceived efficacy of NRT for smoking cessation & comparisons to “cold turkey” 4) side effects and indirect consequences of NRT use 5) actual cost and cost/benefit 6) knowledge of NRT development and regulatory oversight Common Themes Across All Groups (AA and EA) Primacy of motivation: “they have to want to quit smoking for those to be effective” “if you don’t really want to quit you could try all of that stuff but if you don’t really want to quit, it ain’t going to happen” “I don’t think that they really help though because it is the individual alone who has to quit the smoking” Concerns about safety: “NRT could affect other medications you’re taking” “You’re taking a chance. Because you already know what’s going to happen when you smoke, but with the patch, or the pill, or all those things, you don’t know what’s going to happen. You’re really taking a chance” “there could be something in me, that I am allergic to, and it could cause problems” “Isn’t the nicotine that causes cancer?” “Well, it’s a poison, if you over use it, like anything else, it’s going to be harmful“ Need for more information / Openness to learn more: “My question is will it kill me to smoke a cigarette while using the products” “You know more about cigarette studies and how they’ll kill you than you know on the stuff to save you. You know, how many people stopped this month?” “If you are prescribed a certain amount of doses of a capsule and you miss a dose by mistake or are not able to get the dose, what harm can it cause to your body?” “We don’t know what is in them. There could be something in them that could cause cancer” “As far as the commercials alone I can’t determine a success rate on the product itself. Maybe it works” Doubts of Efficacy / Concerns of Cost: “I’m not going to spend $42 for them to sit in my medicine chest b/c it’s not going to work” Citations: 1 Hammond, et al. (2004). Addiction, 99, Cokkinides, et al. (2005). Am J Prev Med, 28, Fu, et al. (2005). Am J Health Promotion, 20, Related Survey Data: AAEAp Ever use of NRT: 26%56%;.03 Nicotine is cause of cancer (% agree):83%65%n.s. Nicotine is cause of heart attacks68%69%n.s. NRT products help people quit31%72%.003 There is risk for becoming dependent42%78%.01